New HIV drug classes on the horizon.
Opar
Alisa
A
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000494:pharmacology / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D023581:HIV Fusion Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D006801:Humans; D000077592:Maraviroc; D019713:Receptors, CCR5 / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000187:drug effects; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use
D019380:Anti-HIV Agents; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; D014230:Triazoles; D000077592:Maraviroc